VEGFA and wet macular degeneration: Currently, even though anti-VEGF antibody based drugs such as ranibizumab, which inhibit CNV, have become a routine treatment for wet AMD treatment (Hernandez-Zimbron et al., 2018), certain clinical studies showed that subretinal fibrosis could occur after anti-VEGF treatment (Daniel et al., 2014).